HLS THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.93 CAD | -5.30% |
|
-17.26% | -0.51% |
| May. 09 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Q2 fiscal 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.877
USD
Average target price
4.174
USD
Spread / Average Target
+45.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.51% | 96.7M | |
| +20.94% | 72.16B | |
| -1.26% | 23.88B | |
| +8.25% | 8.35B | |
| +5.13% | 8.29B | |
| -19.42% | 8.18B | |
| +5.56% | 4.81B | |
| +16.83% | 4.4B | |
| -1.83% | 4B | |
| -1.65% | 3.92B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- Transcript : HLS Therapeutics Inc., Q2 2021 Earnings Call, Aug 05, 2021
